Inoviq Ltd (AU:IIQ) has released an update.
INOVIQ Ltd has made significant strides in its exosome technology, with increased adoption of its NEURO-NET and EXO-NET products by diagnostic and biopharma companies, and the successful transfer of its breast cancer monitoring test to a high-throughput platform for commercialization. The company also strengthened its corporate structure by appointing Mary Harney to its Board and completing a capital raise of $9.4 million to support ongoing development. These developments position INOVIQ as a rising player in the cancer diagnostics and neurological disease markets.
For further insights into AU:IIQ stock, check out TipRanks’ Stock Analysis page.
